Cite
HARVARD Citation
Schoser, B. et al. (2021). Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet neurology. 20 (12), pp. 1027-1037. [Online].